Is Amgen Stock Underperforming the S&P 500?

Headquartered in Thousand Oaks, California, Amgen Inc. (AMGN) discovers, develops, manufactures, and delivers medicines for some of the deadliest diseases. Companies worth $10 billion or more are generally described as “large-cap” stocks, and Amgen’s market cap of roughly $154.9 billion places it firmly in this category, highlighting its substantial size, operational stability, and influence within the drug sector.

Its strong cash position ranks among the strongest in biotech, providing the flexibility to acquire promising pipeline assets that could drive long-term growth. By focusing on areas of high unmet medical need, it is leveraging deep expertise to create solutions that tangibly improve lives, demonstrating strategic foresight and real-world impact.